Literature DB >> 34954313

Rapid assessment of Opisthorchis viverrini IgG antibody in serum: A potential diagnostic biomarker to predict risk of cholangiocarcinoma in regions endemic for opisthorchiasis.

Rutchanee Rodpai1, Vor Luvira2, Lakkhana Sadaow1, Wattana Sukeepaisarnjaroen3, Amnat Kitkhuandee2, Krisada Paonariang2, Oranuch Sanpool1, Wannaporn Ittiprasert4, Victoria H Mann4, Pewpan M Intapan1, Paul J Brindley4, Wanchai Maleewong5.   

Abstract

BACKGROUND: Opisthorchiasis is caused by an infection with fish-borne liver flukes of the genus Opisthorchis. Opisthorchiasis frequently leads to chronic inflammation in the biliary tract and is classified as a group 1 biological carcinogen by the International Agency for Research on Cancer: a definitive risk for cholangiocarcinoma (CCA).
METHODS: We used the rapid immunochromatographic test (ICT) to detect anti-Opisthorchis viverrini IgG and IgG4 subclass antibodies in sera of patients with CCA. The ICT kits were developed based on soluble antigens excreted and secreted by O. viverrini adult worms.
RESULTS: ICT indicated sera was positive for IgG and IgG4 antibodies, respectively, in 22 (61.1%) and 15 (41.6%) participants of the 36 study participants diagnosed with CCA (P > 0.05). Our study also included groups with other cancers and with liver cirrhosis, where the IgG ICT and IgG4 ICT kits were 27.7% (13/47) and 25.5% (12/47) positive, respectively (P > 0.05). Neither total the IgG ICT nor the IgG4 ICT yielded positive results in a control group of 20 healthy participants. Moreover, the percentage positivity rate using the ICT for total IgG between the CCA group and the other cancers and liver cirrhosis group was significantly different (P < 0.05). By contrast, no significant difference between these groups was apparent in the ICT for IgG4 antibody. The CCA group was 6.53 times more likely to have positive anti-O. viverrini IgG antibody (odds ratio 6.53, P < 0.001) and 3.27 times more likely to have positive anti-O. viverrini IgG4 antibody (odds ratio 3.27, P = 0.010) than the non-CCA group.
CONCLUSION: This information is of potential value for the development of a diagnostic biomarker to predict risk for O. viverrini infection-associated CCA.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Cholangiocarcinoma; Diagnostic biomarker; Helminthiases-associated cancer; Opisthorchiasis; Opisthorchis viverrini; Rapid serodiagnosis

Mesh:

Substances:

Year:  2021        PMID: 34954313      PMCID: PMC9569029          DOI: 10.1016/j.ijid.2021.12.347

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   12.074


  29 in total

1.  New staging system and a registry for perihilar cholangiocarcinoma.

Authors:  Michelle L Deoliveira; Richard D Schulick; Yuji Nimura; Charles Rosen; Gregory Gores; Peter Neuhaus; Pierre-Alain Clavien
Journal:  Hepatology       Date:  2011-04       Impact factor: 17.425

Review 2.  Food-borne trematodiases in Southeast Asia epidemiology, pathology, clinical manifestation and control.

Authors:  Banchob Sripa; Sasithorn Kaewkes; Pewpan M Intapan; Wanchai Maleewong; Paul J Brindley
Journal:  Adv Parasitol       Date:  2010       Impact factor: 3.870

Review 3.  Cholangiocarcinoma.

Authors:  Michela Squadroni; Luca Tondulli; Gemma Gatta; Stefania Mosconi; Giordano Beretta; Roberto Labianca
Journal:  Crit Rev Oncol Hematol       Date:  2016-11-25       Impact factor: 6.312

4.  The ELISA-based detection of anti-Opisthorchis viverrini IgG and IgG4 in samples of human urine and serum from an endemic area of north-eastern Thailand.

Authors:  S Tesana; T Srisawangwong; P Sithithaworn; M Itoh; R Phumchaiyothin
Journal:  Ann Trop Med Parasitol       Date:  2007-10

5.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

6.  Association of antibodies to Opisthorchis viverrini with hepatobiliary disease in northeastern Thailand.

Authors:  M Itoh; C Pairojkul; W Thamawit; P Sithithaworn; D Tiwawech; T Uttaravicien; T Shirai; N Ito
Journal:  Am J Trop Med Hyg       Date:  1994-10       Impact factor: 2.345

7.  Serum antibody responses in opisthorchiasis.

Authors:  P S Akai; S Pungpak; W Chaicumpa; V Kitikoon; Y Ruangkunaporn; D Bunnag; A D Befus
Journal:  Int J Parasitol       Date:  1995-08       Impact factor: 3.981

8.  High prevalence of opisthorchiasis in rural populations from Khammouane Province, central Lao PDR: serological screening using total IgG- and IgG4-based ELISA.

Authors:  Weeraya Phupiewkham; Rutchanee Rodpai; Somchith Inthavongsack; Sakhone Laymanivong; Tongjit Thanchomnang; Lakkhana Sadaow; Patcharaporn Boonroumkaew; Oranuch Sanpool; Penchom Janwan; Pewpan M Intapan; Wanchai Maleewong
Journal:  Trans R Soc Trop Med Hyg       Date:  2021-12-02       Impact factor: 2.184

Review 9.  Risk Factors for Cholangiocarcinoma in Thailand: A Systematiczzm321990Review and Meta-Analysis

Authors:  Siriporn Kamsa-ard; Supot Kamsa-ard; Vor Luvira; Krittika Suwanrungruang; Patravoot Vatanasapt; Surapon Wiangnon
Journal:  Asian Pac J Cancer Prev       Date:  2018-03-27

10.  Serum IgG as a Marker for Opisthorchis viverrini-Associated Cholangiocarcinoma Correlated with HER2 Overexpression.

Authors:  Attapol Titapun; Anchalee Techasen; Prakasit Sa-Ngiamwibool; Paiboon Sithithaworn; Vor Luvira; Tharatip Srisuk; Apiwat Jareanrat; Hasaya Dokduang; Watcharin Loilome; Bandit Thinkhamrop; Narong Khuntikeo
Journal:  Int J Gen Med       Date:  2020-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.